Vinpocetine Nanostructure Lipid Carrier Research

Objective Prepare Vinpocetine loaded nanostructured lipid carrier （VIN-NLC） andinvestigate their physicochemical properties. To study the pharmaceutics properties of the VIN-NLC, in order to evaluate the potential application of VIN-NLC.Methods VIN-NLC was prepared by the melt ultrasonication method. Box-Behnkenexperimental design was used for the optimization procedure, with the mixed lipidconcentration, emulsifier concentration and mixed lipid to drug as the independent variables,and the particle diameter, the encapsulation efficiency, the drug loading as the responsevariables. Under the optimal conditions, the particle diameter, entrapment efficiency, drugloading, Zeta potential were measured. The formulation of VIN-NLC was optimized based onits appearance, color and dispersing properties. The lyophilized nanoparticles were developed toimprove the stability of VIN-NLC. The cell model of Alzheimer’s disease （AD） was set up bymeans of inducing PC12cells with Aβ_25-35. The median inhibitory concentration of PC12cellswas detected by MTT assay.Results Under the optimal conditions, the particle diameter, entrapment efficiency, drugloading, Zeta potential were （89.33±3.05） nm,（94.16±3.35）%,（3.30±0.12）%,（-30.1±0.48）mV.10%mannitol was ensured to protect nanoparticles. The median inhibitory concentrationof Aβ_25-35inhibiting PC12cells growth was21.42μmol·L-1, Aβ_25-35at concentration of20.00μmol·L-1inducing PC12cells could develop an ideal AD cell model.Conclusion Through melt ultrasonication method and Box-Behnken experimental designproduce VIN-NLC with smaller particle diameter and higher entrapment efficiency. MTT assayshowed that various concentration of VIN-NLC could significantly increase the cell viabilityinduced by Aβ_25-35. VIN-NLC has broad application prospects.